Francesco Grossi
YOU?
Author Swipe
View article: Transformer-based AI approach to unravel long-term, time-dependent prognostic complexity in patients with advanced NSCLC and PD-L1 ≥50%: insights from the pembrolizumab 5-year global registry
Transformer-based AI approach to unravel long-term, time-dependent prognostic complexity in patients with advanced NSCLC and PD-L1 ≥50%: insights from the pembrolizumab 5-year global registry Open
Background With nearly one-third of patients with advanced non-small cell lung cancer (NSCLC) and PD-L1 Tumor Proportion Score≥50% surviving beyond 5 years following first-line pembrolizumab, long-term outcomes challenge traditional paradi…
Characteristics of patients with suspected cardiac amyloidosis in Tuscany and Umbria: Insights from the cardiac amyloidosis RegistRY (CARRY) Open
The CARRY registry highlights the clinical characteristics of patients with suspected CA, revealing that despite educational efforts, suspicion remains biased towards older patients with advanced disease. Increased awareness and earlier di…
View article: Biomarker testing implementation for molecularly targeted therapy in non-small cell lung cancer patients
Biomarker testing implementation for molecularly targeted therapy in non-small cell lung cancer patients Open
Background: Recent advancements in identifying druggable molecular drivers in lung adenocarcinoma (LUAD), have transformed treatment paradigms. In recent years, Next Generation Sequencing (NGS) has gained momentum as an essential tool for …
View article: Real-world outcomes of subsequent treatment strategies after durvalumab consolidation in stage III unresectable non-small cell lung cancer
Real-world outcomes of subsequent treatment strategies after durvalumab consolidation in stage III unresectable non-small cell lung cancer Open
Platinum-based chemotherapy was the predominant treatment after durvalumab consolidation. Immunotherapy rechallenge was associated with the best survival outcome in selected cases, warranting further investigation.
Impact of very-high-power-short duration catheters on fluid overload biomarker after atrial fibrillation ablation Open
Background Very-high-power-short duration (vHPSD) catheters are associated with less irrigation fluid load then standard (STD) ablation catheters. However, the impact of this fluid reduction on biomarkers in pulmonary vein isolation (PVI) …
Clinical impact of very high‐power‐short‐duration catheters on biomarkers after atrial fibrillation ablation Open
Background Very high‐power short‐duration (vHPSD) catheters are associated with less irrigation fluid load than standard (STD RF) ablation catheters. However, the impact of this fluid reduction on biomarkers in pulmonary vein isolation (PV…
Pooled analysis of oral vinorelbine as single agents in patients with advanced NSCLC Open
This pooled analysis showed that weekly oral VRN is a valid option, with an acceptable safety profile, in this population of patients with advanced NSCLC, confirming results from previous individual studies.
View article: Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry
Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry Open
Background Pembrolizumab monotherapy is an established front-line treatment for advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) tumor proportion score (TPS)≥50%. However, real-world data on its long-…
Spondyloarthritis and Risk of Malignancy: A Narrative Review on a Still Controversial Issue Open
Current literature regarding cancer risk in rheumatic and musculoskeletal diseases (RMDs) is particularly poor and controversial, even though the incidence of malignancy in some patients with RMDs is considered to be increased compared wit…
View article: Precision oncology implementation in a regional-based health care system: A professional consensus to define the pathway
Precision oncology implementation in a regional-based health care system: A professional consensus to define the pathway Open
The direct observation of the current practice in different health care authorities allowed to define ten statements as solution proposals to solve the identified complexities. This methodological approach could be applied in different org…
View article: Supplementary Figure S6 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer
Supplementary Figure S6 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer Open
Scatter diagram with regression line summarizing the linear regression analysis between the median baseline glycaemia (used as independent variable: x-axes) and median baseline NLR (used as dependent variable: y-axes). 133 patients include…
View article: Supplementary Figure S5 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer
Supplementary Figure S5 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer Open
Kaplan-Meier survival estimates according to the receipt of no diabetes medication, other diabetes medications/insulin therapy only, and metformin therapy (either alone or in combinations). A) Overall Survival whole cohort; patients not re…
View article: Supplementary Figure S1 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer
Supplementary Figure S1 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer Open
Kaplan-Meier survival estimates according to the receipt of any diabetes medication. A) Overall Survival NSCLC matched cohort; patients on any diabetes medication: 14.2 months (95%CI: 9.0 – 17.5; 99 events), patients not receiving diabetes…
View article: Supplementary Figure S2 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer
Supplementary Figure S2 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer Open
Kaplan-Meier survival estimates according to the number of diabetes medications. A) Overall Survival whole cohort; patients on more than one diabetes medications: 15.5 months (95%CI: 11.1-20.6; 79 events), patients on one medication: 12.5 …
View article: Supplementary Figure S5 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer
Supplementary Figure S5 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer Open
Kaplan-Meier survival estimates according to the receipt of no diabetes medication, other diabetes medications/insulin therapy only, and metformin therapy (either alone or in combinations). A) Overall Survival whole cohort; patients not re…
View article: Supplementary Table S8 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer
Supplementary Table S8 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer Open
Summary of baseline characteristics’ distribution between patients on other oral antidiabetic drugs/insulin only and those who were not on diabetes medications.
View article: Supplementary Table S5 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer
Supplementary Table S5 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer Open
Melanoma cohort - summary of baseline characteristics’ distribution after the propensity score matching procedure between patients on diabetes medications and those who were not receiving diabetes medications (ratio 1:3, caliper 0.1).
View article: Supplementary Methods S1 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer
Supplementary Methods S1 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer Open
Tumour micron-environment transcriptome analysis.
View article: Supplementary Figure S7 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer
Supplementary Figure S7 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer Open
A) Heat map of the 770 transcripts analyzed with the Nanostring Pancancer Immune Panel in diabetic samples (n=11) compared with non-diabetic controls (n=11). B) Heat map of selected differently transcripted genes.
View article: Supplementary Table S9 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer
Supplementary Table S9 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer Open
Summary of baseline characteristics’ distribution after the propensity score matching procedure between patients on other antidiabetic drugs/insulin only and those who were not on diabetes medications (ratio 1:3, caliper 0.1).
View article: Supplementary Figure S7 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer
Supplementary Figure S7 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer Open
A) Heat map of the 770 transcripts analyzed with the Nanostring Pancancer Immune Panel in diabetic samples (n=11) compared with non-diabetic controls (n=11). B) Heat map of selected differently transcripted genes.
View article: Supplementary Figure S4 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer
Supplementary Figure S4 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer Open
Kaplan-Meier survival estimates according to the receipt of other diabetes medications and insulin therapy. A) Overall Survival whole cohort; patients on other oral antidiabetic drugs and insulin therapy: 17.5 months (95%CI: 12.8-20.9; 82 …
View article: Supplementary Figure S8 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer
Supplementary Figure S8 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer Open
Volcano plot of differentially regulated genes identified by Nanostring analysis. The Benjamini–Hockberg P-values are correlated to fold-changes in transcripts identified in diabetic samples (n = 11) versus non-diabetic controls (n = 11). …
View article: Supplementary Table S2 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer
Supplementary Table S2 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer Open
Details of diabetes medications.
View article: Supplementary Table S7 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer
Supplementary Table S7 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer Open
Summary of baseline characteristics’ distribution after the propensity score matching procedure between patients on metformin only and patients who were not receiving diabetes medications (ratio 1:3, caliper 0.1).
View article: Supplementary Table S7 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer
Supplementary Table S7 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer Open
Summary of baseline characteristics’ distribution after the propensity score matching procedure between patients on metformin only and patients who were not receiving diabetes medications (ratio 1:3, caliper 0.1).
View article: Supplementary Figure S3 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer
Supplementary Figure S3 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer Open
Kaplan-Meier survival estimates according to the receipt of metformin. A) Overall Survival whole cohort; patients on metformin: 12.4 months (95%CI: 10.5-16.3; 100 events), patients not receiving metformin: 19.0 months (95%CI: 16.4 – 21.1; …